Drugs / BBM-P002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 met primary | ||||||
| Phase 0 | NCT05822739 | Apr 2023 → Oct 2025 | Parkinson disease | Xiangya Hospital of Central South University | Completed | Met primary |
| Phase 11 trial | ||||||
| Phase 1 | NCT07195825 | Dec 2025 → Dec 2027 expected | PDA1 | Shanghai Xinzhi BioMed Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-10 | Belief BioMed (Beijing) Co., Ltd | Results 喜讯 | 信念医药帕金森病基因治疗获国际认可！BBM-P002临床研究论文在《Nature Medicine》发表 beliefbiomed.com ↗
本次临床研究结果表明，BBM-P002各试验剂量均展现出良好的安全性与耐受性， 高剂量组受试者观察到了初步临床获益。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-10 | Belief BioMed (Beijing) Co., Ltd | 喜讯 | 信念医药帕金森病基因治疗获国际认可！BBM-P002临床研究论文在《Nature Medicine》发表 beliefbiomed.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBM-P002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05822739 ↗ |
| Known as | AAVT42 | “We report the 12-month primary safety and tolerability outcomes of a multicenter, open-label, dose-escalation, phase 1 trial evaluating BBM-P002, a new adeno-associated virus...” PMID 42271071 ↗ Jun 2026 |
| Action | Restore | “delivers a therapeutic gene cassette into putamen” NCT07195825 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “BBM-P002 is an AAV-based gene therapy” NCT07195825 ↗ |
| Route | Other | “Stereotactic Bilateral Putamen Injection” NCT07195825 ↗ |